Factors influencing cure rates of non‐dermatophyte mold and Candida onychomycosis: analysis of outcomes in 81 patients who completed treatment

Onychomycosis shows a poor response to current topical, oral, or device‐related antifungal therapies. The aim of this study was to identify factors influencing the cure rates of non‐dermatophyte mold and Candida onychomycosis.

[1]  A. Nagahawatte,et al.  Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients , 2016, The Journal of dermatological treatment.

[2]  A. Nagahawatte,et al.  Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1‐year follow‐up in nine cases , 2015, International journal of dermatology.

[3]  L. Kircik.  Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach. , 2014, Journal of drugs in dermatology : JDD.

[4]  J. L. Fuentes-Allen,et al.  Prevalence and etiology of onychomycosis in the HIV-infected Mexican population. , 2013, European journal of dermatology : EJD.

[5]  B. Piraccini,et al.  Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. , 2012, Journal of the American Academy of Dermatology.

[6]  R. Ranawaka,et al.  Non-dermatophyte mold onychomycosis in Sri Lanka. , 2012, Dermatology online journal.

[7]  Gregory M. Peterson,et al.  Toenail onychomycosis: an important global disease burden , 2010, Journal of clinical pharmacy and therapeutics.

[8]  B. Elewski,et al.  Onychomycosis and diabetes , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  R. Ranawaka,et al.  Onychomycosis caused by Fusarium sp in Sri Lanka: Prevalence, clinical features and response to itraconazole pulse therapy in six cases , 2008, The Journal of dermatological treatment.

[10]  C. Hui,et al.  Analysis of the factors influencing the therapeutic effects of onychomycosis , 2008, Journal of Tongji Medical University.

[11]  Y. Wu,et al.  Analysis of the factors influencing the therapeutic effects of onychomycosis. , 2001, Journal of Tongji Medical University = Tong ji yi ke da xue xue bao.

[12]  Gianni,et al.  Non‐dermatophytic onychomycosis. An understimated entity? A study of 51 cases , 2000, Mycoses.

[13]  B. Piraccini,et al.  Candida onychomycosis in HIV infection. , 1998, European journal of dermatology : EJD.

[14]  K. Goa,et al.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. , 1996, Drugs.

[15]  N. Ryder,et al.  Terbinafine: Mode of action and properties of the squalene epoxidase inhibition , 1992, The British journal of dermatology.

[16]  Á. Hernanz,et al.  Terbinafine Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Superficial Mycoses , 1992 .